US 12,479,791 B2
Cationic lipid
Satoru Matsumoto, Kanagawa (JP); Yoshimasa Omori, Kanagawa (JP); Masahiro Mineno, Kanagawa (JP); Yasuhiro Sawai, Kanagawa (JP); Nozomu Kakimoto, Kanagawa (JP); and Yasutaka Hoashi, Kanagawa (JP)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Appl. No. 17/267,179
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Aug. 8, 2019, PCT No. PCT/JP2019/031411
§ 371(c)(1), (2) Date Feb. 9, 2021,
PCT Pub. No. WO2020/032184, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 2018-151583 (JP), filed on Aug. 10, 2018.
Prior Publication US 2022/0098142 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 229/12 (2006.01); A61K 9/51 (2006.01); C12N 15/113 (2010.01)
CPC C07C 229/12 (2013.01) [A61K 9/5123 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01)] 10 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Chemistry
wherein n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2,
L represents —C(O)O— or —NHC(O)O—,
Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group,
Rb represents a linear C2-9 alkyl group,
Rc represents a hydrogen atom or a linear C2-9 alkyl group,
Rd represents a hydrogen atom or a linear C2-9 alkyl group,
Re represents a linear C2-9 alkyl group, and
Rf represents a linear C2-9 alkyl group,
or a salt thereof.